Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale

Gregory P Strauss, William R Keller, Robert W Buchanan, James M Gold, Bernard A Fischer, Robert P McMahon, Lauren T Catalano, Adam J Culbreth, William T Carpenter, Brian Kirkpatrick, Gregory P Strauss, William R Keller, Robert W Buchanan, James M Gold, Bernard A Fischer, Robert P McMahon, Lauren T Catalano, Adam J Culbreth, William T Carpenter, Brian Kirkpatrick

Abstract

The current study examined the psychometric properties of the Brief Negative Symptom Scale (BNSS), a next-generation rating instrument developed in response to the NIMH sponsored consensus development conference on negative symptoms. Participants included 100 individuals with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder who completed a clinical interview designed to assess negative, positive, disorganized, and general psychiatric symptoms, as well as functional outcome. A battery of anhedonia questionnaires and neuropsychological tests were also administered. Results indicated that the BNSS has excellent internal consistency and temporal stability, as well as good convergent and discriminant validity in its relationships with other symptom rating scales, functional outcome, self-reported anhedonia, and neuropsychological test scores. Given its brevity (13-items, 15-minute interview) and good psychometric characteristics, the BNSS can be considered a promising new instrument for use in clinical trials.

Conflict of interest statement

Conflict of interest

Dr. Carpenter served as a consultant for Eli Lilly, Lundbeck, Bristol Mysers Squib, Genentech, Shire Pharmaceuticals, Astra Zeneca, and Merck. Dr. Kirkpatrick has served as a consultant for Sunovion, Abbott, Boehringer Ingelheim. Dr Buchanan has served as consultant or on the advisory boards of Abbott, Amgen, Astra-Zeneca, Astellas, Bristol-Meyer-Squibb, Cypress Bioscience, EnVivo. Janssen Pharmaceuticals, Inc., NuPathe, Inc, Pfizer, Roche, Schering-Plough, Solvay Pharmaceutical, Takeda, and Wyeth. Dr. Buchanan is also a DSMB member for Cephalon, Pfizer, and Otsuka. Dr. Gold has served as a consultant for Roche, Merck, Pfizer, Bristol Meyers Squibb, and Glaxo Smith Kline.

Dr. McMahon has consulted for Amgen. Drs. Buchanan and Fischer receive royalties from UpToDate Incorporated. Dr. Strauss, Dr. Keller, Mr. Culbreth, and Ms. Catalano have no financial relationships with commercial interests.

Copyright © 2012 Elsevier B.V. All rights reserved.

References

    1. Andreasen NC. Negative symptoms in schizophrenia: Definition and reliability. Arch Gen Psychiatry. 1982;39:784–788.
    1. Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item Negative Symptom Assessment. J Psychiatr Res. 1993;27:253–258.
    1. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull. 2006;32:238–245.
    1. Blanchard JJ, Kring AM, Horan WP, Gur R. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr Bull. 2011;37 (2):291–299.
    1. Buchanan RW, Carpenter WT. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis. 1994;182 (4):193–204.
    1. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Hetesco-Levy U, Carpenter WT. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164 (10):1593–1602.
    1. Carpenter WT, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145:578–583.
    1. Chapman LJ, Chapman JP. Unpublished test. University of Wisconsin; Madison, WI: 1978. Revised Physical Anhedonia Scale.
    1. Eckblad ML, Chapman LJ, Chapman JP, Mishlove M. Unpublished test. University of Wisconsin; Madison, WI: 1982. The Revised Social Anhedonia Scale.
    1. First MB, Spitzer RL, Gibbon M, Williams JBW. Structural Clinical Interview for DSM-IV Axis I Disorders (SCID-IV) New York: New York State Psychiatric Institute, Biometrics Research; 1997.
    1. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess. 1998;2 (14):7–8.
    1. Forbes C, Blanchard JJ, Bennett M, Horan WP, Kring A, Gur R. Initial development and preliminary validation of a new negative symptom measure: The Clinical Assessment Interview for Negative Symptoms (CAINS) Schizophr Res. 2010;124:36–42.
    1. Gard DE, Kring AM, Gard MG, Horan WP, Green MF. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res. 2007;93:253–260.
    1. Gold JM, Waltz JA, Prentice KJ, Morris SE, Heerey EA. Reward processing in schizophrenia: A deficit in the representation of value. Schizophr Bull. 2008;34:835–847.
    1. Gold JM, Waltz JA, Matveeva TM, Kasanova Z, Strauss GP, Herbener ES, Collins AGE, Frank MJ. Negative symptoms in schizophrenia result from a failure to represent the expected value of rewards: Behavioral and computational modeling evidence. Arch Gen Psychiatry. 2012;69:129–138.
    1. Harvey PD, Koren D, Reichenberg A, Bowie CR. Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr Bull. 2006;32:250–258.
    1. Hawk AB, Carpenter WT, Strauss JS. Diagnostic criteria and five-year outcome in schizophrenia: a report from the International Pilot Study of Schizophrenia. Arch Gen Psychiatry. 1975;32:343–347.
    1. Heerey EA, Gold JM. Patients with schizophrenia demonstrate dissociation between affective experience and motivated behavior. J Abnorm Psychology. 2007;116:268–278.
    1. Horan WP, Kring AM, Gur RE. Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS) Schizophr Res. 2011;132:140–145.
    1. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT. The Schedule for the Deficit Syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30:119–123.
    1. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58:165–171.
    1. Kirkpatrick B, Fenton W, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:296–303.
    1. Kirkpatrick B, Galderisi S. Deficit schizophrenia: an update. World Psychiatry. 2008;7:143–147.
    1. Kirkpatrick B, Strauss GP, Nguyen L, Fischer BF, Daniel D, Cienfuegos A, Marder SR. The Brief Negative Symptom Scale: Psychometric Properties. Schizophr Bull. 2011;37:300–305.
    1. Nuechterlein KH, Green MF. MATRICS Consensus Cognitive Battery. Los Angeles: MATRICS Assessment, Inc; 2006.
    1. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799–812.
    1. Strauss GP, Frank MF, Waltz JA, Kasanova Z, Herbener ES, Gold JM. Deficits in Positive Reinforcement Learning and Uncertainty-Driven Exploration are Associated with Distinct Aspects of Negative Symptoms in Schizophrenia. Biol Psychiatry. 2011b;69:424–431.
    1. Strauss GP, Gold JM. A New Perspective on Anhedonia in Schizophrenia. Am J Psychiatry. 2012;169:364–373.
    1. Strauss GP, Harrow M, Grossman LS, Rosen C. Periods of Recovery in Deficit Syndrome Schizophrenia: A 20-Year Multifollowup Longitudinal Study. Schizophr Bull. 2010a;36:788–799.
    1. Strauss GP, Hong LE, Gold JM, Buchanan RW, Keller WR, Fischer BA, McMahon RP, Catalano LT, Culbreth AJ, Carpenter WT, Kirkpatrick B. Factor structure of the Brief Negative Symptom Scale. Schizophr Res in press.
    1. Strauss GP, Robinson BM, Waltz JA, Frank MJ, Kasanova Z, Herbener ES, Gold JM. Patients with Schizophrenia Demonstrate Inconsistent Preference Judgments for Affective and Non-Affective Stimuli. Schizophr Bull. 2011a;37:1295–1304.
    1. Strauss GP, Sandt AR, Catalano LT, Allen DN. Negative symptoms and depression predict psychological well-being in individuals with schizophrenia. Comp Psychiatry 2012
    1. Wechsler D. Wechsler Test of Adult Reading (WTAR) San Antonio, TX: The Psychological Corporation; 2001.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する